2023-02-24
Notice of Completion of Series A Funding of Approximately 560 Million Yen
CTBE has completed Series A Funding in January 2023. A total of approximately 560 million yen in series A funding was raised through the following investors.
Waseda Innovation Fund No. 3 Investment Partnership
Teijin Limited
Japan Science and Technology Agency
AXA Life Insurance Co., Ltd.
NextG Investment Business Limited Liability Partnership
Sun Global Co., Ltd.
With this funding, CTBE will accelerate the commercialization of artificial ligaments for anterior cruciate ligament reconstruction surgery.
2024-12-24
CoreTissue BioEngineering announces the renewal of its corporate website
2024-11-11
Yoji Jokura will present at ”The 62nd Annual Meeting of the Japanese Society for Artificial Organs”
2024-10-15
CTBE has been selected as a coworking member of the Japan Innovation Campus in Silicon Valley, USA.
2024-08-29
CTBE announces start of clinical trial for regenerative ligament for ACL reconstruction using decellularization technology
2024-07-30
Japanese medtech startup, CoreTissue BioEngineering, becomes first company accepted into accelerator program backed by Mitsubishi Corporation (Americas) and Fogarty Innovation